RSS Feeds
Optimal Prediction of Diabetes
- Michael P. Stern, MD;
- Ken Williams, MS; and
- Steven M. Haffner, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
The Web site http://www.statcoder.com contains a large collection of physician-support software that can readily be “hot synched” into a personal digital assistant. This Web site was brought to our attention by one of our younger colleagues, who told us that she and others use these programs frequently for patient evaluation and counseling. Among the software programs available on this Web site is the National Cholesterol Education Program Adult Treatment Guidelines III, which includes the Framingham risk equation, an equation analogous to the one presented in our paper. Also available is an equation for estimating preoperative risk. There is no reason why a diabetes risk calculator could not be added to the collection of programs on this or similar Web sites.
It is true that the oral glucose tolerance test is “easy to order,” but this is rarely done because of inconvenience and high cost. We recently estimated that the indirect cost attributable to 2 hours of peoples' time would be several billion dollars if widespread screening with the oral glucose tolerance test were implemented in the segment of the U.S. population deemed eligible for screening by the American Diabetes Association (1).
Michael P. Stern, MD
Ken Williams, MS
Steven M. Haffner, MD
University of Texas Health Science Center; San Antonio, TX 78229
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
